Last reviewed · How we verify
NCT06580730: ETP-1
Endovascular Treatment for Stroke Post 1 Day （24 Hours）
NA trial testing Endovascular treatment in Acute Ischemic Stroke in 224 participants. Not yet recruiting.
1 August 2026
Quick facts
| Lead sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 224 |
| Start date | 1 September 2024 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 August 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Endovascular treatment
- Standard medical treatment — full drug profile →
Conditions studied
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Who can join
Adults 18 to 80, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute ischemic stroke (AIS) is one of the leading causes of disability and mortality worldwide. The treatment of this condition is time-critical, with the key to effective therapy being the early recanalization of the occluded vessel and restoration of blood flow to salvage the ischemic penumbra tissue. Currently, the time window for endovascular treatment in the anterior circulation can be extended up to 24 hours. Exploring endovascular treatments for patients beyond this time window (from 24 hours to 30 days) could mean hope for a greater number of AIS patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06580730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Endovascular treatment
Trials testing the same drug.
- NCT07323368 — Advancing Reperfusion Therapy for Ischemic Stroke: Perfusion-guided Endovascular Intervention for Medium Vessel Occlusio · NA · recruiting
- NCT07263308 — Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2 · Phase 3 · recruiting
- NCT07315633 — An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies fo · recruiting
- NCT06588543 — Patient-specific Planning of Minimally Invasive Brain Interventions Based on Vascular-hemodynamic Mapping · recruiting
- NCT06101667 — Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-B · NA · recruiting
Other recruiting trials for Acute Ischemic Stroke
Currently open trials in the same condition.
- NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
- NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
- NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting
Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials
Trials by the same sponsor.
- NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
- NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
- NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
- NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
- NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06580730 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Last refreshed: 5 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06580730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing